TABLE 2.
Characteristics | Total (n) | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|---|
Hazard ratio (95% CI) | P value | Hazard ratio (95% CI) | P value | ||
≤60 | 224 | Reference | |||
>60 | 275 | 1.577 (0.440-5.648) | 0.484 | ||
T stage | 492 | ||||
T2 | 189 | Reference | |||
T3&T4 | 303 | 3.294 (0.612-17.727) | 0.165 | ||
N stage | 426 | ||||
N0 | 347 | Reference | |||
N1 | 79 | 3.516 (0.778-15.896) | 0.102 | ||
M stage | 458 | ||||
M0 | 455 | Reference | |||
M1 | 3 | 59.383 (6.520-540.817) | <0.001 | 22.369 (0.681-734.908) | 0.041 |
Gleason score | 499 | ||||
6&7&8 | 357 | Reference | |||
9&10 | 142 | 4.842 (1.206-19.436) | 0.026 | 0.542 (0.084-3.502) | 0.520 |
Primary therapy outcome | 438 | ||||
PD&SD&PR | 97 | Reference | |||
CR | 341 | 0.111 (0.022-0.552) | 0.007 | 0.165 (0.023-1.175) | 0.072 |
Residual tumor | 468 | ||||
R0 | 315 | Reference | |||
R1&R2 | 153 | 2.598 (0.696-9.694) | 0.155 | ||
PSA (ng/ml) | 442 | ||||
<4 | 415 | Reference | |||
≥4 | 27 | 10.479 (2.471-44.437) | 0.001 | 4.829 (0.886-26.310) | 0.069 |
TK1 | 499 | 2.226 (1.130-4.385) | 0.021 | 1.980 (0.850-4.613) | 0.113 |